Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of May 2023. The filing, dated May 10, 2023, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is headquartered in Geneva, Switzerland, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement containing quantitative data.
Material Changes
No material financial changes versus prior periods are detailed in the text of this filing. The document solely references the issuance of a press release without summarizing its specific content or financial impact.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or specific risk factors. It notes that the attached press release is incorporated into the company's registration statements on Form F-3 and Form S-8.
Key Facts for Investor Verification
- Review the full text of the press release dated May 10, 2023 (Exhibit 99.1), as the specific news or data is not summarized in this filing.
- Verify the incorporation of this press release into the active registration statements (Form F-3 No. 333-255089 and Form S-8 No. 333-255124).
- Confirm that no other financial disclosures were made in this specific Form 6-K beyond the reference to the press release.